MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation
- PMID: 9603457
- DOI: 10.1002/(SICI)1521-4141(199805)28:05<1524::AID-IMMU1524>3.0.CO;2-T
MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation
Abstract
Proteolysis of the invariant chain (li) leads to the generation of abundant MHC class II-associated invariant chain peptides (CLIP), which bind in the MHC class II binding groove via supermotifs in a manner similar to that of antigenic peptides. We have engineered an li vector with the capacity to express any antigenic peptide of interest instead of CLIP, for T cell stimulation. When peripheral blood mononuclear cells (PBMC) were pulsed with li hybrids encoding T cell epitopes of tetanus toxin or acetylcholine receptor, stimulation of T cells was dramatically enhanced compared to stimulation after priming with either the native or recombinant proteins. Site-specific insertion of antigenic sequences into the CLIP region promoted enhanced antigenicity of li hybrids which were shown to be processed intracellularly in a chloroquine-sensitive compartment. Naturally processed T helper epitopes were visualized directly on the surface of PBMC and identified as analogs of CLIP associated with MHC class II molecules. This novel li vector provides a flexible and efficient system for the delivery of defined peptide epitopes to T cells which might be useful in the development of specific vaccines and in the study of intracellular processing.
Similar articles
-
Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.Int Immunol. 2000 Nov;12(11):1561-8. doi: 10.1093/intimm/12.11.1561. Int Immunol. 2000. PMID: 11058576
-
Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.Cancer Res. 2003 Sep 1;63(17):5587-94. Cancer Res. 2003. PMID: 14500399
-
MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.Int Immunol. 2003 Nov;15(11):1291-9. doi: 10.1093/intimm/dxg128. Int Immunol. 2003. PMID: 14565927
-
Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.Expert Opin Biol Ther. 2006 Dec;6(12):1311-21. doi: 10.1517/14712598.6.12.1311. Expert Opin Biol Ther. 2006. PMID: 17223739 Review.
-
CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Vaccine. 2012. PMID: 22386748 Review.
Cited by
-
Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class II-associated invariant chain peptide of the invariant chain.Infect Immun. 2002 May;70(5):2676-80. doi: 10.1128/IAI.70.5.2676-2680.2002. Infect Immun. 2002. PMID: 11953411 Free PMC article.
-
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.Oncoimmunology. 2019 Jan 11;8(3):1558663. doi: 10.1080/2162402X.2018.1558663. eCollection 2019. Oncoimmunology. 2019. PMID: 30723591 Free PMC article.
-
Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses.Sci Rep. 2018 Oct 9;8(1):15020. doi: 10.1038/s41598-018-33375-1. Sci Rep. 2018. PMID: 30301933 Free PMC article.
-
Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome.Front Immunol. 2013 Dec 13;4:443. doi: 10.3389/fimmu.2013.00443. Front Immunol. 2013. PMID: 24379812 Free PMC article. Review.
-
Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.J Exp Med. 1999 May 17;189(10):1659-68. doi: 10.1084/jem.189.10.1659. J Exp Med. 1999. PMID: 10330445 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials